Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01914757
First received: July 31, 2013
Last updated: November 30, 2016
Last verified: November 2016
  Purpose
The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.

Condition Intervention Phase
Asthma
Biological: Benralizumab
Biological: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.


Secondary Outcome Measures:
  • Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.

  • Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
  • Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
  • Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

  • Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

  • Change in Asthma Rescue Medication Use [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)

  • Home Lung Function Assessments Based on PEF [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow [PEF])

  • Proportion of Nights With Awakening Due to Asthma [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma

  • Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.

  • Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.

  • Number of Patients With >=1 Asthma Exacerbation [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
  • Time to First Asthma Exacerbation [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
  • Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations [ Time Frame: Immediately following the first administration of study drug through Study Week 56. ]
    Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)

  • Pharmacokinetics of Benralizumab [ Time Frame: Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60 ]
    Mean PK Concentration at each visit

  • Immunogenicity of Benralizumab [ Time Frame: Pre-treatment until end of follow-up ]
    Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at >=2 post-baseline assessments (with >=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

  • Extent of Exposure [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
    Extent of exposure is defined as the duration of treatment in days

  • Mean Change From Baseline to Week 56 in AQLQ(S)+12 [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
    AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of >=0.5 are considered clinically meaningful.

  • Change From Baseline to Week 56 in EQ-5D-5L VAS [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
    EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

  • Mean Work Productivity Loss Due to Asthma [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.

  • Mean Productivity Loss Due to Asthma in Classroom [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.

  • Number of Participants That Utilized Health Care Resources [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
  • Patient and Clinician Assessment of Response to Treatment [ Time Frame: Immediately following the first administration of study drug through Study Week 56 ]
    CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.


Enrollment: 2508
Study Start Date: August 2013
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Benralizumab 30 mg q.4 weeks
Benralizumab administered subcutaneously every 4 weeks
Biological: Benralizumab
Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
Experimental: Benralizumab 30 mg q.8 weeks
Benralizumab administered subcutaneously every 8 weeks
Biological: Benralizumab
Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
Placebo Comparator: Placebo
Placebo administered subcutaneously
Biological: Placebo
Placebo subcutaneously on study week 0 until study week 52 inclusive.

  Eligibility

Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures
  2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1
  3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250µg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1.
  4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral corticosteroids and additional asthma controllers. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. For ICS/LABA combination preparations, the mid-strength approved maintenance dose in the local country will meet this ICS criterion.

Exclusion criteria:

  1. Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
  4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01914757

  Show 217 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Mark Fitzgerald, MD, PhD, Professor of Medicine The Lung Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver Canada
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01914757     History of Changes
Other Study ID Numbers: D3250C00018
Study First Received: July 31, 2013
Results First Received: September 8, 2016
Last Updated: November 30, 2016

Keywords provided by AstraZeneca:
Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases

ClinicalTrials.gov processed this record on May 24, 2017